Results 21 to 30 of about 718 (153)

Epilepsy in Juvenile Neuronal Ceroid Lipofuscinosis

open access: yesPediatric Neurology Briefs, 2000
The clinical characteristics of epilepsy and optimal antiepileptic drug therapy were surveyed in 60 patients (mean age 16 years, range 5-33) with juvenile neuronal ceroid lipofuscinosis (JNCL), followed at the University of Helsinki ...
J Gordon Millichap, Millichap, J. Gordon
core   +2 more sources

Molecular mechanisms of the juvenile form of Batten disease: important role of MAPK signaling pathways (ERK1/ERK2, JNK and p38) in pathogenesis of the malady

open access: yesBiology Direct, 2018
Background Mutations in the CLN3 gene lead to so far an incurable juvenile-onset neuronal ceroid lipofuscinosis (JNCL) or Batten disease that starts at the age of 4–6 years with a progressive retinopathy leading to blindness. Motor disturbances, epilepsy
Dmitry G. Shpakovski   +3 more
core   +2 more sources

Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease). [PDF]

open access: yesFront Psychiatry, 2023
BackgroundJuvenile neuronal ceroid lipofuscinosis (JNCL, CLN3) is a childhood-onset neurodegenerative disease with prominent symptoms comprising a pediatric dementia syndrome.
Ostergaard JR.
europepmc   +2 more sources

Lamotrigine Therapy in Neuronal Lipofuscinosis

open access: yesPediatric Neurology Briefs, 1999
Lamotrigine (LTG) long-term anticonvulsant therapy was evaluated in 29 patients, aged 6-28 years (mean, 14 years), with juvenile neuronal ceroid lipofuscinosis (JNCL), followed for 1-6 years (mean, 3 years) at the Hospital for Children and Adolescents ...
J Gordon Millichap
core   +2 more sources

A mouse mutant deficient in both neuronal ceroid lipofuscinosis-associated proteins CLN3 and TPP1. [PDF]

open access: yesJ Inherit Metab Dis, 2023
Abstract Late‐infantile neuronal ceroid lipofuscinosis (LINCL) and juvenile neuronal ceroid lipofuscinosis (JNCL) are inherited neurodegenerative diseases caused by mutations in the genes encoding lysosomal proteins tripeptidyl peptidase 1 (TPP1) and CLN3 protein, respectively.
Sleat DE   +10 more
europepmc   +2 more sources

Treatment of non-epileptic episodes of anxious, fearful behavior in adolescent juvenile neuronal ceroid lipofuscinosis (CLN3 disease). [PDF]

open access: yesFront Neurol, 2023
BackgroundRecurrent non-epileptic episodes of frightened facial and body expression occur in more than half of post-adolescent patients with juvenile neuronal ceroid lipofuscinosis (JNCL, CLN3 disease).
Ostergaard JR.
europepmc   +2 more sources

Age at onset and gene variants predict lifespan and disease duration in childhood neuronal ceroid lipofuscinoses. [PDF]

open access: yesDev Med Child Neurol
This original article is commented on by Mole on pages 156–157 of this issue. Abstract Aim To address disease progression in a cohort of patients with childhood‐onset neuronal ceroid lipofuscinosis (NCL), a group of genetic disorders leading to progressive dementia. Method In this retrospective study, selected clinical features (age at onset, at death,
Simonati A   +4 more
europepmc   +2 more sources

A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature. [PDF]

open access: yesFront Genet, 2021
The neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, are a group of autosomal recessive lysosomal storage disorders that are characterized by neurodegeneration, progressive cognitive decline, motor impairment, ataxia, loss of vision ...
Nicolaou P   +6 more
europepmc   +2 more sources

Overview of advances in educational and social supports for young persons with NCL disorders. [PDF]

open access: yesBiochim Biophys Acta Mol Basis Dis, 2020
Vision loss, dementia, and motor and speech declines all impact the educational experience of individuals with Batten disease and can adversely impact effective learning.
Elmerskog B   +6 more
europepmc   +6 more sources

Mimickers of hydroxychloroquine retinal toxicity. [PDF]

open access: yesClin Exp Ophthalmol
Abstract Hydroxychloroquine (HCQ) retinal toxicity is an important entity that can be challenging to differentiate from its mimickers. Bull's eye maculopathy is the classical presentation of HCQ retinopathy; however, its differential includes several drug‐related retinal toxicities, inherited retinal disorders, and systemic conditions with associated ...
Jones P   +3 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy